Breaking News
Top News
-
Bull vs. Bear: Is Intel Stock a Buy or Sell?
-
The key to TikTok Shop’s blockbuster $4.9-billion quarter? The fastest-growing spenders aren’t Gen Z — they’re over 45
-
Investors Should Buy the Stocks of These 3 OpenAI Partners Regardless of What Happens to OpenAI
-
Recent inflation data was ‘bad news,’ Fed’s Goolsbee says
-
Weyerhaeuser Q1 Earnings Call Highlights
-
Wabash National Q1 Earnings Call Highlights
-
WisdomTree Q1 Earnings Call Highlights
-
W.P. Carey Q1 Earnings Call Highlights
-
Xenia Hotels & Resorts Q1 Earnings Call Highlights
-
Germany and Europe Have Bigger Trump Problems Than U.S. Troop Withdrawal
-
Turning $250K Into $1M in 5 Years: Why This Real Estate Promise Is a Red Flag
-
58-year-old outdoor retailer nears Chapter 11 filing
-
Vertex (VRTX) Named Top Biotech Pick for 2026 by BofA
-
Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth
-
PTC Therapeutics (PTCT) Reports Positive Huntington’s Disease Trial Results
-
Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli
-
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential
-
Genmab (GMAB) Rated Outperform on Oncology Pipeline
-
Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings
-
Argenx (ARGX) Outlook Improves on Autoimmune Pipeline Expansion
2026-02-05








